Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent + Gemzar in sarcomatoid or poor-risk metastatic renal cell carcinoma
NCT00556049Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, gemcitabine in metastatic renal cell carcinoma (mRCC), sponsored by Massachusetts General Hospital. Started Dec 2007; status: completed.
02
Drugs
sunitinibgemcitabine
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00556049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556049.